Tom Frohlich - 13 Dec 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC.

Role: Chief Operating Officer
Signature: /s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 13 Dec 2022
Net transactions value: -$245,805
Form type: 4
Filing time: 15 Dec 2022, 15:28:37 UTC
Previous filing: 09 Nov 2022
Next filing: 02 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KDNY	Common Stock	Options Exercise	$4,200	+10,000	+6.9%	$0.4200^*	153,907	13 Dec 2022	Direct
transaction	KDNY	Common Stock	Sale	$250,005	-10,000	-6.5%	$25.00	143,907	13 Dec 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KDNY	Employee Stock Option (right to buy)	Options Exercise	$0	-10,000	-19%	$0.000000	43,847	13 Dec 2022	Common Stock	10,000	$0.4200	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F3	The stock option vested as to 25% of the total shares on March 6, 2021, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.